Back to top

Apogee Therapeutics downgraded to Neutral from Outperform at Mizuho

Mizuho analyst Joseph Catanzaro downgraded Apogee Therapeutics (APGE) to Neutral from Outperform with a price target of $135, up from $110, after t...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Apogee Therapeutics Inc. (APGE)